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Abstract: Closed loop anesthesia delivery (CLAD) systems can help anesthesiologists efficiently
achieve and maintain desired anesthetic depth over an extended period of time. A typical
CLAD system would use an anesthetic marker, calculated from physiological signals, as real-time
feedback to adjust anesthetic dosage towards achieving a desired set-point of the marker. Since
control strategies for CLAD vary across the systems reported in recent literature, a comparative
analysis of common control strategies can be useful. For a nonlinear plant model based on well-
established models of compartmental pharmacokinetics and sigmoid-Emax pharmacodynamics,
we numerically analyze the set-point tracking performance of three output-feedback linear
control strategies: proportional-integral-derivative (PID) control, linear quadratic Gaussian
(LQG) control, and an LQG with integral action (ILQG). Specifically, we numerically simulate
multiple CLAD sessions for the scenario where the plant model parameters are unavailable for
a patient and the controller is designed based on a nominal model and controller gains are held
constant throughout a session. Based on the numerical analyses performed here, conditioned on
our choice of model and controllers, we infer that in terms of accuracy and bias PID control
performs better than ILQG which in turn performs better than LQG. In the case of noisy
observations, ILQG can be tuned to provide a smoother infusion rate while achieving comparable
steady state response with respect to PID. The numerical analysis framework and findings
reported here can help CLAD developers in their choice of control strategies. This paper may
also serve as a tutorial paper for teaching control theory for CLAD.
Keywords: Closed-loop control, physiological systems, LQG, PID, integral action, anti-windup,
compartmental models, sigmoid-Emax, quantitative systems pharmacology
1. INTRODUCTION
More than 230 million patients undergo major surgeries
world-wide under anesthesia (Weiser et al. (2008)). During
major surgeries performed under general anesthesia (GA)
(Brown et al. (2010)), conventionally, an anesthesiolo-
gist would monitor relevant physiological signals that are
known to be associated with anesthetic depth, and man-
ually adjust the drug dose. For example, changes in oscil-
latory patterns in the scalp electroencephalogram (EEG)
has been shown to be correlated with behaviorally-defined
changes in unconsciousness levels during GA (Purdon et al.
(2013)). Such structured drug-dependent changes in the
EEG signals have allowed developments of automated
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EEG-based closed-loop anesthesia delivery (CLAD) sys-
tems that can provide precise control of brain states under
anesthesia (Bickford (1950); Schwilden et al. (1989); Ab-
salom et al. (2002); Dumont et al. (2009); Shanechi et al.
(2013); Puri et al. (2016); Yang et al. (2019)). Analogous
systems are also available for blood pressure (BP)-based
CLAD (Ngan Kee et al. (2007)).
A typical CLAD system works in a cyclic mode at a fast
rate (∼ 0.1 s−1) where in each cycle a computer calculates
a scalar anesthetic marker from real-time physiological
signals (say, EEG or BP) and uses a feedback control
strategy to determine the adjustment of drug-dosage for
the next cycle. As this iterative procedure continues over
time, the anesthetic marker ideally would approach the
user-prescribed set-point. The utility of such autopilot
systems are in personalized medicine as they can aid anes-
thesiologists achieve patient-specific precise drug-dosing
efficiently, even under resource constrained environments
(Dumont and Ansermino (2013); Absalom et al. (2011)).
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The CLAD systems reported in prior research, vary with
respect to different features, e.g., regime of anesthesia,
anesthetic drug, signal modality, marker definition, control
strategy, and plant model, just to name a few. For ex-
ample, the classical output-feedback proportional-integral-
derivative (PID) control strategy and its variants have
been found to be useful in CLAD applications in human
studies (Dumont et al. (2009); Puri et al. (2016); West-
over et al. (2015)). The more recent development of using
an estimated-state feedback-based optimal control strat-
egy via linear quadratic Gaussian (LQG) regulation have
yielded promising results for maintenance of medically-
induced coma in animal models (Shanechi et al. (2013)).
The success of both PID and LQG, as general control
paradigms for CLAD, motivated us to compare them
through a numerical experiment in this work.
In this numerical study of CLAD, we consider a specific
nonlinear state-space model as the plant model. Here the
state dynamics, driven by the drug infusion, is described by
a four-compartment linear pharmacokinetic (PK) model.
The observation dynamics, relating the anesthetic marker
and the dynamic state in the effect compartment, is as-
sumed to be described by a sigmoid-Emax pharmacody-
namic (PD) model (Meibohm and Derendorf (1997)). We
choose realistic values of model parameters based on a
pair of well-established models in literature for propofol-
based PK and corresponding EEG-based PD (Schnider
et al. (1998, 1999)). We linearize this nonlinear plant model
around a steady state value and use the resulting linear
state-space model to determine control parameters. Since
LQG is known to have robustness issues (Doyle (1978))
and model-misspecification can lead to steady state errors
during set-point tracking, we also consider LQG with an
additional integral action (ILQG) on the output error. To
address practical constraints, we impose actuator satura-
tion and zero-order holds explicitly. We consider different
operating conditions characterized by observation noise
and pump-update rates, as well as control parameters. For
fixed target trajectory and a given operating condition, we
simulate CLAD for multiple subjects to mimic a practical
scenario when only a nominal plant model, instead of the
true one, is available for controller design.
In the ensuing discussion, Sec. 2 presents the core equa-
tions for the plant and the control strategies. Sec. 3
presents our numerical simulation design, results and as-
sociated discussion. Finally, Sec. 4 summarizes our work.
2. METHODS
2.1 Nonlinear plant model
We model the pharmacokinetics (PK) using a first-order
ordinary differential equation as,
x˙(t) = Ax(t) +Bu(t) (1)
where, x˙ indicates dx/dt. Transition matrix, A, and input
scaling matrix, B, are prescribed based on a four com-
partment mammillary model assumption as proposed by
Shafer and Gregg (1992), where the effect site is aug-
mented to a three-compartment model as an additional
fourth compartment (much smaller in volume relative to
the central compartment). The mass of drug in all the
compartments at any instant of time, t, is indicated by
x(t) = [x1(t), x2(t), x3(t), x4(t)]
T , u(t) denotes scalar infu-
sion rate function, B = [1, 0, 0, 0]T and transition matrix
is given by,
A =
−(k10 + k12 + k13 + k14) k21 k31 k41k12 −k21 0 0k13 0 −k31 0
k14 0 0 −k41
 (2)
Note, that u(t) ≥ 0 and xi(t) ≥ 0 ∀ i ∈ {1, 2, 3, 4} and
∀ t ≥ 0. The PK model described above is illustrated
in Fig. 1. We model the pharmacodynamic (PD) 3 rela-
tionship between a scalar-valued dose-dependent function,
say y(t), of the physiological signal of interest and the
effect site amount, x4(t), using the following sigmoid-Emax
model,
y(t) = E0 + Emax
(
(x4(t)/x50)
γ
1 + (x4(t)/x50)γ
)
(3)
where, E0, Emax > 0, x50 > 0, and γ > 0 are scalar
parameters. In the ensuing discussion, the symbol ‘(t)’, in
the notations indicating dynamic variables, will be omitted
for brevity. In the computational simulation studies that
Fig. 1. Schematic of a 4-compartment PK model
we perform here, the core plant model taking input u(t)
and generating output y(t) is given by Eqs. (1) and (3).
The nonlinear plant model is characterized by the subject-
specific PK-PD parameters ΘP = {A, x50, γ, Emax, E0}.
2.2 Linear control strategy with output feedback
Steady state relationships: For linear control design for
set-point tracking, we determine relationships among y, x
and u for a steady state condition. Imposing the steady
state condition, x˙ = 0 in Eq. (1), and denoting the
constant values at steady state as yss, xss and uss, we
obtain
xss = −A−1Buss , (4)
x4,ss = [0, 0, 0, 1]xss . (5)
yss can be calculated by substituting x4,ss in Eq. (3).
When either yss or uss is specified, one can use the
aforementioned algebraic relationships to calculate the rest
of the steady state quantities.
Linearizing about a steady state: The relationship be-
tween the y and u, via Eqs. (1) and (3), is nonlinear.
To incorporate a linear feedback control framework to
regulate y around a steady state value, characterized by
3 Conventionally, k14 and k41 are treated as PD parameters
(Schnider et al. (1999)), but here, for convenience, we consider them
as PK model parameters so as to maintain separate parameter sets
for the state and the observation equations.
the tuple (yss, xss, uss), we linearize Eq. (3) about this
steady state,
y − yss =
(
dy
dx4
)
x4,ss
(x4 − x4,ss) + higher order terms
(6)
Ignoring the higher-order terms, we obtain a new set of
equations in terms of dynamic quantities that denote per-
turbations with respect to respective steady state values,
˙˜x = Ax˜+Bu˜ (7)
y˜ = Cx˜ (8)
where, y˜ ≡ y − yss, x˜ ≡ x− xss, u˜ ≡ u− uss, and
C =
[
0 0 0
(
dy
dx4
)
x4,ss
]
(9)
where,
(
dy
dx4
)
x4,ss
=
Emax
x50
γ(x4,ss/x50)
γ−1
(1 + (x4,ss/x50)γ)2
(10)
PID control: To achieve set-point tracking of y about a
constant set-point ysp, we consider linear system of equa-
tions in Eqs. (7) and (8) where linearization is achieved
around a user-prescribed state (yo, xo, uo). Using PID
control gains, KP , KI and KD, tuned based on this lin-
ear system, we implement the following control strategy
(Astro¨m and Murray (2010)),
upid = uo +KP (y − ysp) +KI
∫
(y − ysp)dt+KDy˙
(11)
where, ysp denotes the user-prescribed set-point which
may or may not be equal to yo, but should be in the
neighborhood around yo where the linear dynamics regime
can still be assumed. The parameter set for the PID is
given by ΘPID = {KP ,KI ,KD, A, x50, γ, Emax, E0, uo}.
This parameter set includes controller gains (KP ,KI ,KD)
as well as the parameters of the nominal linear model
that will depend both on the nonlinear plant parameters
(A, x50, γ, Emax, E0) as well as the state (uo) at which the
linearization occurs.
LQG control: To achieve constant set-point tracking
when using LQG strategy, we reformulate the problem in
the form of,
x˙ = A(x− xsp) +B(u− usp) + w (12)
y − ysp = Co(x− xsp) + v (13)
where, w and v are continuous-time zero-mean Gaussian
white noise processes characterized by positive-definite
covariance matrix W and positive scalar V , respectively
(Crassidis and Junkins (2011)). The Co is determined from
Eq. (10) using the linearization state (yo, xo, uo) prescribed
in terms of either yo or uo (see Sec. 2.2.1). We assume that
during a session the controller parameters that depend on
(yo, xo, uo) will be kept constant, but the set-point ysp may
vary around yo in a session. With the problem setup in
Eqs. (12) and (13), we can pose the LQG optimal control
problem as,
{u?(t)} = argminE [J({u(t)})] (14)
J ≡
∫ ∞
0
(x− xsp)TQ(x− xsp) + (u− usp)TR(u− usp) dt
(15)
Fig. 2. Schematic block diagram of CLAD simulation setup
such that Eq. (12) holds at every time-point, and E[·]
indicates an expectation operation. Assuming the system
(A,B) is stabilizable and (A,Co) is detectable and matri-
cesQ andR are positive semi-definite and positive definite,
respectively, the solution of the aforementioned optimal
control problem leads to a steady state linear quadratic
regulator with control action ulqg given by,
ulqg = usp −KC(x̂− xsp) (16)
where, x̂ is the output of a steady state Kalman filter,
˙̂x = (A−KECo)(x̂− xsp) +B(u− usp) +KE(y − ysp)
(17)
Controller gain matrix KC depends on A, B, Q and R.
Estimator gain matrix KE depends on A, Co, W and V .
The formulae to calculate KC and KE can be found in
literature (Athans (1971); Crassidis and Junkins (2011)).
The parameter set for the PID is given by ΘLQG =
{Q,R,W, V,A, x50, γ, Emax, E0, uo}.
ILQG control: To minimize any steady state bias that
can ensue due to model mismatch between the plant and
the controller, we add an integral action to minimize the
steady state errors. To do this we consider an additional
state z driven by the tracking error,
z˙ = ysp − y , such that, (18)
uilqg = ulqg +KIz (19)
where, KI > 0 is an additional user-prescribed gain.
The parameter set for the ILQG is given by ΘILQG =
{KI , Q,R,W, V, A, x50, γ, Emax, E0, uo}. Since we are in-
terested in how the LQG performance changes with regard
to the current CLAD problem in the presence and absence
of an integral action, we explicitly specify KI . This is in
the same spirit as the LQG servocontroller designs that
can be simulated using the lqgtrack function in MATLAB
(2019). Alternatively, one can also design KI implicitly
within the LQG framework (Grimble (1979)).
Additional constraints for CLAD simulation: In the
context of CLAD, practical considerations require u ≥
umin = 0 and u ≤ umax; the latter constraint can be
due to constraints on the physiological system and/or
the mechanical actuation system. To mimic this in our
simulation, we allow output of the controller, say uc (such
that c ∈ {pid, lqg, ilqg}), goes through a saturation block
prescribed as,
u = uc , if 0 < uc < umax,
u = 0 , if uc ≤ 0,
u = umax , if uc ≥ umax, (20)
to yield the control signal u that is input to the drug
delivery system. Within the drug delivery system, the
modulation of infusion rates for anesthetic fluids is a
mechanical phenomenon which can have a short transient
before the infusion rate stabilizes around the desired flow
rate. To simulate this condition without modeling the drug
delivery dynamics explicitly we impose a zero-order hold
(zoh) condition on u, such that the flow rate u is updated
at an interval Tu, and held constant until the next update.
A similar zoh condition is applied on the output side
assuming that it is sampled at rate Ty which may or may
not be equal to Tu. To mimic the noise in the observations,
we also add Gaussian white noise with variance V and
sampled at every interval Ty, to the observation. If Ty = Tu
holds, then one can alternatively choose to model plant
and controller dynamics in discrete-time governed by in-
cremental dynamic equations. However, this would require
the increment time-interval to enter the system matrices
that are used to calculate controller gains. Furthermore,
modeling the plant in continuous time is conceptually
closer to the physiological phenomena governing the true
PK-PD phenomena. Therefore, in this work, we try to keep
the plant and control blocks independent of any prescribed
time-interval, but add the aforementioned constraints, via
user-prescribed values of umax, Tu and Ty, externally in
the complete simulation block diagram (Fig. 2).
Table 1. Performance metrics for PID (Fig.3(a-
d)), LQG with ρ = 10−13 (Fig.4(a-d)), LQG
with ρ = 10−6 (Fig.4(e-h)), ILQG with KI =
10, ρ = 10−13 (Fig.5(a-d)) , LQG with KI =
1, ρ = 10−6 (Fig.5(e-h)). Median (min, max)
values of performance metrics from 44 CLAD
simulations per case.
Fig. 60Tu V I (%) B (%) uavg
3(a) 5s 10−6 0.4(0.4,0.4) 0.1(0.1,0.1) 5.6(4.0,7.3)
3(b) 5s 10−4 3.2(3.2,3.3) 0.2(0.1,0.2) 5.6(4.0,7.3)
3(c) 10s 10−6 0.3(0.3,0.4) 0.1(0.1,0.1) 5.7(4.1,7.3)
3(d) 10s 10−4 2.4(2.3,2.4) 0.2(0.2,0.3) 5.6(4.0,7.3)
4(a) 5s 10−6 2.6(1.2,6.7) -2.5(-6.6,1.6) 5.4(4.2,6.6)
4(b) 5s 10−4 4.2(3.7,7.0) -2.7(-6.8,1.7) 5.4(4.2,6.6)
4(c) 10s 10−6 2.6(1.5,6.5) -2.4(-6.4,1.4) 5.4(4.2,6.6)
4(d) 10s 10−4 3.6(3.0,6.8) -2.6(-6.6,1.9) 5.4(4.2,6.6)
4(e) 5s 10−6 16.9(3.4,47.2) -16.9(-47.2,4.7) 4.6(4.6,4.6)
4(f) 5s 10−4 14.8(5.5,42.8) -14.8(-42.8,7.0) 4.6(4.6,4.6)
4(g) 10s 10−6 17.2(3.4,47.5) -17.0(-47.5,4.3) 4.6(4.6,4.6)
4(h) 10s 10−4 15.2(4.7,44.7) -15.2(-44.7,7.0) 4.6(4.6,4.6)
5(a) 5s 10−6 1.0(0.9,1.2) 0.5(0.2,0.9) 5.6(4.1,7.2)
5(b) 5s 10−4 3.6(3.5,3.7) 0.3(-0.3,1.2) 5.6(4.1,7.2)
5(c) 10s 10−6 1.0(1.0,1.2) 0.5(0.1,1.0) 5.7(4.1,7.2)
5(d) 10s 10−4 2.9 (2.8,3.0) 0.5(-0.1,1.3) 5.7(4.1,7.2)
5(e) 5s 10−6 1.2(0.9,1.6) 0.7(0.5,0.9) 5.6(4.1,7.3)
5(f) 5s 10−4 3.7(3.5,3.9) 0.6(0.3,0.9) 5.6(4.1,7.3)
5(g) 10s 10−6 1.5(1.0,1.9) 0.8(0.6,1.0) 5.7(4.1,7.3)
5(h) 10s 10−4 2.8(2.6,3.1) 0.8(0.5,1.1) 5.7(4.1,7.3)
3. RESULTS
3.1 CLAD simulation setup
Plant model parameters: As candidate plant model pa-
rameters we used the weight, height, age and sex infor-
mation available for Np = 44 patients reported in prior
work (Dumont et al., 2009, Table A1). For the PK-PD
model, we used the model parameters reported for 3-
compartment propofol pharmacokinetics (Schnider et al.,
1998, Table 2) and corresponding EEG-based pharma-
codynamics (Schnider et al., 1999, Table 3), where for
the latter we use only the age-adjusted parameters for
the ascending sigmoidal function in the bi-phasic response
(Schnider et al., 1999, Fig. 1). We set E0 = 0 and Emax = 1
since they reflect a constant shift and scaling. Per sugges-
tion by Shafer and Gregg (1992), we use k41 = 10
−5k14.
Fig. 3. PID: Simulated trajectories for 45 patients (in-
cluding the nominal subject, highlighted in solid blue)
with 4 sets of (60Tu, V ): (a) (5 s, 10
−6), (b) (5 s, 10−4),
(c) (10 s, 10−6), (d) (10 s, 10−4). Also see Table 1.
.
Simulation parameters: Each simulation mimics a CLAD
session of duration, Tmax = 600min. In all simulations,
we maintain the maximum allowable infusion rate for a
patient weighing W (kg) as umax = 1mg/kg/min×W . We
set Ty = Tu for simplicity. To mimic a practical situation
where the CLAD system is activated after a patient is
anesthetized, we run the system in an open-loop mode for
Tind = 5min with a fixed infusion rate of u = umax/10
prior to activating the closed-loop mode. For the closed-
loop mode, the following target profile is maintained:
ysp = 0.8 for t ∈ (Tind, Tmax/4], then ysp = 0.64 for
t ∈ (Tmax(1/4), Tmax(2/4)], followed by ysp = 0.88 for
t ∈ (Tmax(2/4), Tmax(3/4)], and finally back to ysp = 0.9
for t ∈ (Tmax(3/4), Tmax]. We also simulate disturbance
profiles at t = 225min, 375min and 575min where the
effect-site dynamic state x4 is scaled by a factor 2, 0.5 and
0.5, respectively, for a brief period (= 10Tu).
Controller parameters: For any given simulation run
we linearize the PK-PD model, available to the con-
troller, around a steady state value of uo = umax/10.
For LQG and ILQG, we set Q to be a diagonal matrix
such that diag(Q) =
[
1/(x1,max − xo)2, 1/(x2,max − xo)2,
1/(x3,max − xo)2, ρ/(x4,max − xo)2
]
, where xmax is calcu-
lated using Eq. (4) and umax. We set scalar R = 1/(umax−
uo)
2. For the process noise variance W we choose a diag-
onal matrix such that diag(W ) = 10−6V [1, 1, 1, 1]. For
the PID controller, we determine KP , KI and KD for
linear system parameters A, B and Co by invoking the
Matlab function, pidtune with its default setting of bal-
ance between performance and robustness. Since we will
be simulating with noisy observations, we incorporate a
derivative filter such that transfer function contribution to
the derivative component of the PID transfer function is
KDs/(Tfs+1) where we set Tf = 5Tu. Furthermore, since
we have actuation saturation, to avoid integral error build-
up, we employ the following anti-windup strategy (Astro¨m
and Murray (2010)): when the output of the controller, uc,
falls outside the range [umin, umax] we enforce a zero input
into the integrator blocks of both the PID and the ILQG.
3.2 CLAD simulations
For each control strategy we simulate for every patient set-
point tracking with Tu ∈ {5/60min, 10/60min}, and V =
{10−6, 10−4} under conditions described in the following
subsection. For each combination of (Tu, V ), we simulate:
Fig. 4. LQG: Simulated trajectories for 45 patients (in-
cluding the nominal subject, highlighted in solid
blue) with 4 sets of (60Tu, V ): (a,e) (5 s, 10
−6), (b,f)
(5 s, 10−4), (c,g) (10 s, 10−6), (d,h) (10 s, 10−4). (a-d)
ρ = 1013,KI = 0, (e-h) ρ = 10
6,KI = 0. See Table 1.
a PID-based CLAD (Fig. 3(a-d)), an ILQG-based CLAD
with two control designs [ρ = 10−13,KI = 10] (Fig. 5(a-d))
and [ρ = 10−6,KI = 1] (Fig. 5(e-h)), and an LQG-based
CLAD simulation under same conditions, but with KI = 0
(Fig. 4(a-d) and Fig. 4(e-h)). For each of these operating
conditions, we simulate CLAD sessions for Np subjects
such that the nominal plant and true plant are different.
In these simulations, every subject is characterized by a
respective ΘP value, whereas controller parameters are
characterized by a fixed set of parameters ΘC determined
based on a nominal model of the plant, ΘPnom. To calcu-
late the ΘPnom, we consider a nominal subject (age = 35.5
years, height = 177.5 cm, weight = 79.5 kg, male) using
the median of each of these features. The parameters,
for this nominal patient are: k10 = 0.4282min
−1, k12 =
0.4005min−1, k13 = 0.1958min−1, k21 = 0.0664min−1,
k31 = 0.0035min
−1, k41 = 0.4560min−1, x50 = 6.8 ×
10−5mg, γ = 3.0965. All simulations are performed using
MATLAB (2019)/Simulink. To assess the performance
across controller designs and across multiple simulation
conditions, we use the following inaccuracy and bias met-
rics (Dumont et al. (2009)),
Inaccuracy, I = median{100|(yk − ysp)/ysp|} (21)
Bias, B = median{100(yk − ysp)/ysp} (22)
where, yk denotes the observation at the k-th time-point.
We also report the average infusion, uavg, calculated across
each simulated session.
3.3 Discussion
Our final assessment of controller performance across the
simulated CLAD sessions is based on both the numerical
outputs of I , B , uavg (Table 1) and visual inspection of
output and control trajectory plots (Figs. 3, 4, 5). The in-
accuracy and bias metrics for the PID are found to be lower
Fig. 5. ILQG: Simulated trajectories for 45 patients
(including the nominal subject, highlighted in solid
blue) with 4 sets of (60Tu, V ): (a,e) (5 s, 10
−6), (b,f)
(5 s, 10−4), (c,g) (10 s, 10−6), (d,h) (10 s, 10−4). (a-d)
ρ = 1013,KI = 10, (e-h) ρ = 10
6,KI = 1. See Table 1.
than both ILQG and LQG. The ILQG simulations show
better set-point tracking performance relative to LQG,
e.g. compare Fig.4(a-d) vs. Fig. 5(a-d) and Fig.4(e-h) vs.
Fig. 5(e-h). Since the model mis-specification (difference
between true and nominal models) has a significantly ad-
verse effect on the performance metrics for Fig. 4(e-h) this
particular LQG design is unacceptable for any practical
CLAD implementation. Also, from visual inspection we
can infer that PID control leads to faster convergence to
set-point relative to LQG or ILQG, but all three control
strategies are able to provide stable regulation. The plots
in Figs. 3(a-d), 5(a-d), and 5(e-f) indicate that by lowering
ρ (the relative weighting of state cost to input cost in
the LQG quadratic objective function) we can tune the
ILQG to achieve a control signal that is not as sensitive
to the observation noise and leads to tracking perfor-
mance comparable to PID. In all the simulations except
for Fig. 4(e-h), the median uavg is found to be almost
similar (at least to the first significant digit). A plausible
reason for this observation is that in all cases, except
Fig. 4(e-h), the control strategies are able to converge on
the same average infusion rate that would achieve and
track the same ysp for most part of the simulated sessions
(as indicated by the median I ≤ 4.2% across all these
sessions, which is markedly lower than the same metric
in Fig. 4(e-h)). Furthermore, the influence of the transient
dynamics of the control signal due to set-point changes and
noise become less pronounced in the total infused volume
estimate (used to calculate uavg) over such long sessions. In
the summary our aforementioned observations reflect the
salient differences among the three control strategies. The
PID controller is designed to have fast, stable dynamics
on the output feedback error. On the other hand, the
LQG controller is designed to minimize the quadratic cost
Eq. (15) and a higher penalty on the deviation of state
trajectory from xsp (relative to the deviation of control
from usp) can lead to better set-point tracking of ysp by y.
For ILQG, the addition of integral action leads to a sub-
optimal performance relative to the LQG cost function but
with improved steady state set-point tracking relative to
LQG, and comparable to PID.
4. CONCLUSION
In this work, we compared three control strategies: PID,
LQG, and ILQG for a CLAD application. For the CLAD
problem of set-point tracking of output from a single-
input single-output system described by Eqs. (1) and (3),
we draw the following inference from our analyses. PID
can help with faster convergence to set-point when a set-
point change occurs. Once a set-point is achieved, PID,
ILQG and LQG can each provide stable set-point tracking.
LQG requires a very high penalty on state cost relative
to actuation cost to provide acceptable set-point tracking
performance, but adding an integral action via an ILQG
can lead to acceptable tracking performance with lower
relative cost. In the presence of observation noise, ILQG
can be tuned to achieve temporally smoother actuation
with comparable set-point tracking performance relative
to a PID controller. Our results indicate that an integral
action, incorporated within a linear feedback control strat-
egy, can improve set-point tracking of pharmacodynamic
response in such a CLAD setting.
We envisage that this work will be useful to guide con-
troller choices in future CLAD designs, and to numerically
assess their performance prior to their usage in animal
models or humans. Since the framework involving PK-PD
model considered in this study is quite general (Meibohm
and Derendorf (1997)), our work can be relevant to CLAD
applications beyond the specific anesthetic drug and phys-
iologic signal definitions of the assumed PK-PD model
(Schnider et al. (1998, 1999)). Furthermore, this paper
may also serve as a tutorial introduction to applications
of control theory in CLAD systems.
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